FDA’s Chief Scientist Has Full Plate To Concentrate On: Clinical Research
This article was originally published in The Tan Sheet
Executive Summary
FDA Chief Scientist Frank Torti will be asked to concentrate on clinical research when he assumes the newly created position in May, the agency says
You may also be interested in...
Von Eschenbach Resigning In January With BTC Debate In His Legacy
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed
Von Eschenbach Resigning In January With BTC Debate In His Legacy
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed
Von Eschenbach Resigning In January With BTC Debate In His Legacy
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed